12:00 AM
 | 
Jan 26, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RecAP: Phase II started

AM-Pharma began the double-blind, placebo-controlled, international Phase II STOP-AKI trial to evaluate 0.4, 0.8 and 1.6 mg/kg IV RecAP once daily for 3 days in about 290 patients with sepsis-associated...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >